

BENZTROPINE MESYLATE- benztropine mesylate tablet
QUAGEN PHARMACEUTICALS LLC


BENZTROPINE MESYLATE TABLETS, USP 0.5 mg, 1 mg and 2 mg

Rx only

DESCRIPTION

Benztropine mesylate, USP is a synthetic compound containing structural features found in atropine and diphenhydramine.

It is a crystalline white powder, very soluble in water, designated as 3 α -(Diphenylmethoxy)-1 α H, 5 α H-tropane methanesulfonate, with the following structural formula:



Each benztropine mesylate tablet, USP for oral administration contains benztropine mesylate 0.5 mg, 1 mg or 2 mg.

Each tablet contains the following inactive ingredients: microcrystalline cellulose, pregelatinized starch, magnesium stearate.

CLINICAL PHARMACOLOGY

Benzotropine mesylate possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism.

In the isolated guinea pig ileum, the anticholinergic activity of this drug is about equal to that of atropine; however, when administered orally to unanesthetized cats, it is only about half as active as atropine.

In laboratory animals, its antihistaminic activity and duration of action approach those of pyrilamine maleate.

INDICATIONS AND USAGE

Benztropine mesylate tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism.

Useful also in the control of extrapyramidal disorders [except tardive dyskinesia - see *PRECAUTIONS*] due to neuroleptic drugs (e.g., phenothiazines).

CONTRAINDICATIONS

Hypersensitivity to benztropine mesylate tablets.

Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

WARNINGS

Safe use in pregnancy has not been established.

Benztropine mesylate may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.

When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants.

Since benztropine mesylate contains structural features of atropine, it may produce anhidrosis. For this reason, it should be administered with caution during hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, the alcoholic, those who have central nervous system disease, and those who do manual labor in a hot environment. Anhidrosis may occur more readily when some disturbance of sweating already exists. If there is evidence of anhidrosis, the possibility of hyperthermia should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired. Severe anhidrosis and fatal hyperthermia have occurred.

PRECAUTIONS

General

Since benztropine mesylate has cumulative action, continued supervision is advisable. Patients with a tendency to tachycardia and patients with prostatic hypertrophy should be observed closely during treatment.

Dysuria may occur, but rarely becomes a problem. Urinary retention has been reported with benztropine mesylate.

The drug may cause complaints of weakness and inability to move particular muscle

groups, especially in large doses. For example, if the neck has been rigid and suddenly relaxes, it may feel weak, causing some concern. In this event, dosage adjustment is required.

Mental confusion and excitement may occur with large doses, or in susceptible patients. Visual hallucinations have been reported occasionally. Furthermore, in the treatment of extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), in patients with mental disorders, occasionally there may be intensification of mental symptoms. In such cases, antiparkinsonian drugs can precipitate a toxic psychosis. Patients with mental disorders should be kept under careful observation, especially at the beginning of treatment or if dosage is increased.

Tardive dyskinesia may appear in some patients on long-term therapy with phenothiazines and related agents, or may occur after therapy with these drugs has been discontinued. Antiparkinsonism agents do not alleviate the symptoms of tardive dyskinesia, and in some instances may aggravate them. Benztropine mesylate is not recommended for use in patients with tardive dyskinesia.

The physician should be aware of the possible occurrence of glaucoma. Although the drug does not appear to have any adverse effect on simple glaucoma, it probably should not be used in angle-closure glaucoma.

Drug Interactions

Antipsychotic drugs such as phenothiazines or haloperidol; tricyclic antidepressants [see **WARNINGS**].

Pediatric Use

Because of the atropine-like side effects, benztropine mesylate should be used with caution in pediatric patients over three years of age [see **CONTRAINDICATIONS**].

ADVERSE REACTIONS

The adverse reactions below, most of which are anticholinergic in nature, have been reported and within each category are listed in order of decreasing severity.

Cardiovascular

Tachycardia.

Digestive

Paralytic ileus, constipation, vomiting, nausea, dry mouth.

If dry mouth is so severe that there is difficulty in swallowing or speaking, or loss of appetite and weight, reduce dosage, or discontinue the drug temporarily.

Slight reduction in dosage may control nausea and still give sufficient relief of symptoms. Vomiting may be controlled by temporary discontinuation, followed by resumption at a lower dosage.

Nervous System

Toxic psychosis, including confusion, disorientation, memory impairment, visual hallucinations; exacerbation of preexisting psychotic symptoms; nervousness; depression; listlessness; numbness of fingers.

Special Senses

Blurred vision, dilated pupils.

Urogenital

Urinary retention, dysuria.

Metabolic/Immune or Skin

Occasionally, an allergic reaction, e.g., skin rash, develops. If this can not be controlled by dosage reduction, the medication should be discontinued.

Other

Heat stroke, hyperthermia, fever.

Manifestations - May be any of those seen in atropine poisoning or antihistamine overdosage: CNS depression, preceded or followed by stimulation; confusion; nervousness; listlessness; intensification of mental symptoms or toxic psychosis in patients with mental illness being treated with neuroleptic drugs (e.g., phenothiazines); hallucinations (especially visual); dizziness; muscle weakness; ataxia; dry mouth; mydriasis; blurred vision; palpitations; tachycardia; elevated blood pressure; nausea; vomiting; dysuria; numbness of fingers; dysphagia; allergic reactions, e.g., skin rash; headache; hot, dry, flushed skin; delirium; coma; shock; convulsions; respiratory arrest; anhidrosis; hyperthermia; glaucoma; constipation.

Treatment - Physostigmine salicylate, 1 mg to 2 mg, SC or IV, reportedly will reverse symptoms of anticholinergic intoxication.¹ A second injection may be given after 2 hours if required. Otherwise treatment is symptomatic and supportive. Induce emesis or perform gastric lavage (contraindicated in precomatose, convulsive, or psychotic states). Maintain respiration. A short-acting barbiturate may be used for CNS excitement, but with caution to avoid subsequent depression; supportive care for depression (avoid convulsant stimulants such as picrotoxin, pentyleneetetrazol, or bemegride); artificial respiration for severe respiratory depression; a local miotic for mydriasis and cycloplegia; ice bags or other cold applications and alcohol sponges for hyperpyrexia, a vasopressor and fluids for circulatory collapse. Darken room for photophobia.

1 Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. 206: 1963-1965, Nov. 25, 1968.

DOSAGE AND ADMINISTRATION

Benztropine mesylate tablets should be used when patients are able to take oral medication.

The injection is especially useful for psychotic patients with acute dystonic reactions or other reactions that make oral medication difficult or impossible. It is recommended also when a more rapid response is desired than can be obtained with the tablets.

Because of cumulative action, therapy should be initiated with a low dose which is increased gradually at five or six-day intervals to the smallest amount necessary for optimal relief. Increases should be made in increments of 0.5 mg, to a maximum of 6 mg, or until optimal results are obtained without excessive adverse reactions.

Postencephalitic and Idiopathic Parkinsonism - The usual daily dose is 1 mg to 2 mg, with a range of 0.5 mg to 6 mg orally or parenterally.

As with any agent used in parkinsonism, dosage must be individualized according to age and weight, and the type of parkinsonism being treated. Generally, older patients, and thin patients cannot tolerate large doses. Most patients with postencephalitic parkinsonism need fairly large doses and tolerate them well. Patients with a poor mental outlook are usually poor candidates for therapy.

In idiopathic parkinsonism, therapy may be initiated with a single daily dose of 0.5 mg to 1 mg at bedtime. In some patients, this will be adequate; in others 4 mg to 6 mg a day may be required.

In postencephalitic parkinsonism, therapy may be initiated in most patients with 2 mg a day in one or more doses. In highly sensitive patients, therapy may be initiated with 0.5 mg at bedtime, and increased as necessary.

Some patients experience greatest relief by taking the entire dose at bedtime; others react more favorably to divided doses, two to four times a day. Frequently, one dose a day is sufficient, and divided doses may be unnecessary or undesirable.

The long duration of action of this drug makes it particularly suitable for bedtime medication when its effects may last throughout the night, enabling patients to turn in bed during the night more easily, and to rise in the morning.

When benztropine mesylate is started, do not terminate therapy with other antiparkinsonian agents abruptly. If the other agents are to be reduced or discontinued, it must be done gradually. Many patients obtain greatest relief with combination therapy.

Benztrapine mesylate tablets may be used concomitantly with Carbidopa-Levodopa, or with levodopa, in which case periodic dosage adjustment may be required in order to maintain optimum response.

Drug-Induced Extrapramidal Disorders - In treating extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), the recommended dosage is 1 mg to 4 mg once or twice a day orally. Dosage must be individualized according to the need of the patient. Some patients require more than recommended; others do not need as much.

When extrapyramidal disorders develop soon after initiation of treatment with neuroleptic drugs (e.g., phenothiazines), they are likely to be transient. One to 2 mg of benztropine mesylate tablets two or three times a day usually provides relief within one or two days. After one or two weeks, the drug should be withdrawn to determine the continued need for it. If such disorders recur, benztropine mesylate can be reinstituted.

Certain drug-induced extrapyramidal disorders that develop slowly may not respond to benztropine mesylate.

HOW SUPPLIED

Benztrapine Mesylate Tablets, USP, for oral use, are supplied in the following forms:

0.5 mg: White to off-white, round, flat faced bevel edged tablets debossed "T" above "14" below the bisect on one side and plain on the other side. They are supplied as follows.

Bottles of 1000 tablets	NDC 70752-123- 11
----------------------------	----------------------

1 mg: White to off-white, oval shape, tablets debossed "T" to the left and "15" to the right of the bisect on one side and plain on the other side. They are supplied as follows.

Bottles of 100 tablets	NDC 70752-124- 10
Bottles of 1000 tablets	NDC 70752-124- 11

2 mg: White to off-white, round, flat faced bevel edged tablets debossed "T" above "16" below the bisect on one side and plain on the other side. They are supplied as follows.

Bottles of 100 tablets	NDC 70752-125- 10
Bottles of 1000 tablets	NDC 70752-125- 11

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Dispense in well-closed containers as defined in the USP.

Keep out of reach of children.

Manufactured by:

Quagen Pharmaceuticals LLC

West Caldwell, NJ 07006

52007

Rev. 03/25

PRINCIPAL DISPLAY PANEL - 0.5 mg Tablet Bottle Label

NDC 70752-123-10

Benztropine

Mesylate

Tablets, USP

0.5 mg

Rx only

100 Tablets

Quagen

NDC 70752-123-10

Benztropine Mesylate Tablets, USP

0.5 mg

100 Tablets

Rx only

QUAGEN PHARMA

Each tablet contains: Benzotropine Mesylate, USP 0.5 mg

USUAL ADULT DOSAGE: For Parkinsonism, 1 to 2 mg daily. For drug induced extrapyramidal disorders, 1 to 4 mg once or twice a day. See full prescribing information.

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Dispense in well-closed containers as defined in the USP.

Keep out of reach of children.

SEALED FOR YOUR PROTECTION.

Manufactured by:
Quagen Pharmaceuticals LLC
West, NJ 07006

MADE IN USA

50013
Rev. 04/25

GTIN 00370752123105

70752-12310-5

1.0" x 1.25"

Non Varnish Area

PRINCIPAL DISPLAY PANEL - 1 mg Tablet Bottle Label

NDC 70752-124-10
Benzotropine Mesylate Tablets, USP
1 mg
Rx only
100 Tablets

Quagen

NDC 70752-124-10

Benzotropine Mesylate Tablets, USP

1 mg

100 Tablets

Rx only

QUAGEN PHARMA

Each tablet contains: Benzotropine Mesylate, USP 1 mg

USUAL ADULT DOSAGE: For parkinsonism, 1 to 2 mg daily. For drug induced extrapyramidal disorders, 1 to 4 mg once or twice a day. See full prescribing information.

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Dispense in well-closed containers as defined in the USP.

Keep out of reach of children.

SEALED FOR YOUR PROTECTION.

Manufactured by:
Quagen Pharmaceuticals LLC
West Caldwell, NJ 07006

MADE IN USA

50015
Rev. 03/25

GTIN 00370752124102

70752-12410-2

1.0" x 1.25"

Non Varnish Area

PRINCIPAL DISPLAY PANEL - 2 mg Tablet Bottle Label

NDC 70752-125-10
Benzotropine Mesylate Tablets, USP
2 mg
Rx only
100 Tablets

Quagen

NDC 70752-125-10

Benztropine Mesylate Tablets, USP

2 mg

**QUAGEN PHARMA**

100 Tablets

Rx only

Each tablet contains: Benzotropine Mesylate, USP 2 mg

USUAL ADULT DOSAGE: For Parkinsonism, 1 to 2 mg daily. For drug induced extrapyramidal disorders, 1 to 4 mg once or twice a day. See full prescribing information.

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Dispense in well-closed containers as defined in the USP.

Keep out of reach of children.

SEALED FOR YOUR PROTECTION.

Manufactured by:
Quagen Pharmaceuticals LLC
West Caldwell, NJ 07006


50017
MADE IN USA
Rev. 04/25

1.0" x 1.25"

NO VARNISH

BENZTROPINE MESYLATE

benztropine mesylate tablet

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70752-123	
Route of Administration	ORAL			
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
BENZTROPINE MESYLATE (UNII: WMJ8TL7510) (BENZTROPINE - UNII:1NHL2J4X8K)		BENZTROPINE MESYLATE	0.5 mg	
Inactive Ingredients				
Ingredient Name			Strength	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)				
MAGNESIUM STEARATE (UNII: 70097M6I30)				
STARCH, PREGELATINIZED CORN (UNII: O8232NY3SJ)				
Product Characteristics				
Color	WHITE (White to Off-White)	Score	2 pieces	
Shape	ROUND (flat beveled edge)	Size	6mm	
Flavor		Imprint Code	T;14	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70752-123-10	100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	08/11/2025	
2	NDC:70752-123-11	1000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	08/11/2025	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA212694	08/11/2025	

BENZTROPINE MESYLATE

benztropine mesylate tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70752-124
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
BENZTROPINE MESYLATE (UNII: WMJ8TL7510) (BENZTROPINE - UNII:1NHL2J4X8K)	BENZTROPINE MESYLATE	1 mg

Inactive Ingredients

Ingredient Name	Strength
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
STARCH, PREGELATINIZED CORN (UNII: O8232NY3SJ)	

Product Characteristics

Color	WHITE (White to Off-White)	Score	2 pieces
Shape	OVAL	Size	11mm
Flavor		Imprint Code	T;15
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70752-124-10	100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	08/11/2025	
2	NDC:70752-124-11	1000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	08/11/2025	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date

ANDA	ANDA212694	08/11/2025	
------	------------	------------	--

BENZTROPINE MESYLATE

benztropine mesylate tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70752-125
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
BENZTROPINE MESYLATE (UNII: WMJ8TL7510) (BENZTROPINE - UNII:1NHL2J4X8K)	BENZTROPINE MESYLATE	2 mg

Inactive Ingredients

Ingredient Name	Strength
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
STARCH, PREGELATINIZED CORN (UNII: O8232NY3SJ)	

Product Characteristics

Color	WHITE (White to Off-White)	Score	2 pieces
Shape	ROUND (flat beveled edge)	Size	7mm
Flavor		Imprint Code	T;16
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70752-125-10	100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	08/11/2025	
2	NDC:70752-125-11	1000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	08/11/2025	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA212694	08/11/2025	

Labeler - QUAGEN PHARMACEUTICALS LLC (073645339)

Registrant - QUAGEN PHARMACEUTICALS LLC (073645339)

Establishment			
Name	Address	ID/FEI	Business Operations
QUAGEN PHARMACEUTICALS LLC		081343942	manufacture(70752-123, 70752-124, 70752-125) , pack(70752-123, 70752-124, 70752-125)

Revised: 6/2025

QUAGEN PHARMACEUTICALS LLC